Key result
Severely elevated NT-proBNP levels (>10000 pg/mL) predicted higher 28-day mortality compared to normal levels in patients hospitalized for pneumonia (OR 3.57; 95% CI 2.03-6.27; P<0.001).
Why the study?
NT-proBNP is increasingly recognized for prognostic value beyond heart failure, prompting evaluation of its prognostic value in pneumonia.
Does elevated NT-proBNP predict 28-day mortality and shorter post-discharge survival in adult patients hospitalized for pneumonia?
Cohort (n=2,805)
No
Does elevated NT-proBNP predict 28-day mortality and shorter post-discharge survival in adult patients hospitalized for pneumonia?
Odds Ratio: 3.57 (95% CI 2.03–6.27)
p-value: p=<0.001
Elevated NT-proBNP levels serve as a strong independent predictor of 28-day mortality and reduced post-discharge survival in patients hospitalized for pneumonia.
May refine pneumonia mortality risk stratification; hypothesis-generating and should not yet change practice.
Background NT-proBNP, traditionally used to assess heart failure, is increasingly recognized for its prognostic value in other diseases. This study evaluates its value in pneumonia.Research design and methods We conducted a retrospective cohort study of adult patients hospitalized for pneumonia at Wan Fang Hospital (2017-2021) to investigate whether elevated NT-proBNP levels predicted poorer outcomes. Logistic regression identified risk factors for 28-day mortality, while the Cox regression model identified predictors of post-discharge survival.Results Among 2,805 patients (79.6 ± 13.4 years, female 45%), the 28-day mortality rate was 18.2%, and the median post-discharge follow-up time was 359 days. Moderately (increased but <10000 pg/mL) and severely (>10000 pg/mL) elevated NT-proBNP levels had higher 28-day mortality compared to normal NT-proBNP; adjusted odds ratios: 2.24 (1.34-3.75, p = 0.002) and 3.57 (2.03-6.27, p < 0.001). Moderately and severely elevated NT-proBNP levels related to shorter survival time than normal NT-proBNP levels; adjusted hazard ratios 1.60 (1.28–2.00, p < 0.001) and 2.03 (1.56–2.63, p < 0.001). All ratios were adjusted with comorbidities, sex, age, and clinical and laboratory tests.Conclusions Elevated NT-proBNP levels predict higher 28-day mortality and shorter survival time in patients with pneumonia across most subpopulations. This marker holds potential as a prognostic biomarker for pneumonia, especially in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Đông et al. (2025) conducted a cohort in pneumonia (n=2,805). Elevated NT-proBNP levels vs. Normal NT-proBNP levels was evaluated on 28-day mortality (OR 3.57, 95% CI 2.03-6.27, p=<0.001). Severely elevated NT-proBNP levels (>10000 pg/mL) predicted higher 28-day mortality compared to normal levels in patients hospitalized for pneumonia (OR 3.57; 95% CI 2.03-6.27; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: